Meronem (Meropenem Anhydrous)

Meropenem belongs to the carbapenem class and works by binding to penicillin‑binding proteins on bacterial cell walls. This inhibits the final steps of peptidoglycan cross‑linking, weakening the wall and causing osmotic lysis, which leads to bacterial death. Its high affinity for multiple PBPs gives it a broad spectrum of activity.

The dosage of Meronem is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals determine the appropriate infusion rate and duration according to established guidelines and patient-specific considerations.

Safety data for meropenem in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should evaluate each case carefully and consider alternative therapies when appropriate.

To order Meronem, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details—including cold‑chain handling if needed—and required import documentation.

Meronem (meropenem) shares a similar spectrum with other carbapenems such as imipenem and ertapenem but offers enhanced stability against many beta‑lactamases and a broader Gram‑negative coverage, including Pseudomonas aeruginosa. Dosing frequency may differ, and meropenem is often preferred for severe infections requiring high‑dose, extended‑infusion regimens.

Meronem should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not store at ambient temperature, as stability may be compromised.

Meronem is administered intravenously as an injectable solution. It is typically given as a slow infusion over 15‑30 minutes, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a controlled setting.

The most serious risks include seizures, especially in patients with pre‑existing CNS disorders or renal impairment, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and nephrotoxicity. Prompt recognition and management of these events are essential during therapy.

Meronem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of severe allergic reactions to beta‑lactam antibiotics.